{"id":25651,"date":"2017-06-12T13:09:51","date_gmt":"2017-06-12T17:09:51","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/?p=25651"},"modified":"2017-06-12T13:09:51","modified_gmt":"2017-06-12T17:09:51","slug":"chemdiv-selected-by-arcus-biosciences-as-the-sole-chemistry-provider-for-its-discovery-screening-collection","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/chemdiv-selected-by-arcus-biosciences-as-the-sole-chemistry-provider-for-its-discovery-screening-collection\/","title":{"rendered":"ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection"},"content":{"rendered":"

SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) — ChemDiv Inc<\/a>., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus\u2019s growing HTS screening collection.\u00a0This collaboration, which utilized Arcus\u2019s medicinal chemistry knowledge and ChemDiv\u2019s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.<\/p>\n

\"ChemDiv\"
\n\u201cA best-in-class drug always starts with a great lead, and our team has learned over the years, going back to our Tularik days, that ChemDiv\u2019s libraries have been carefully designed to increase the likelihood of identifying such great leads,\u201d said Juan Jaen, President and Co-Founder of Arcus Biosciences.<\/p>\n

Jaen added: \u201cArcus currently has a number of small-molecule discovery programs targeted at the regulation of several biological pathways that appear to play important roles in the suppression of effector immune (T and NK) cells. Some of these programs are already fairly mature and will be in the clinic in short order; however, some of the earlier-stage projects will benefit immensely from having access to ChemDiv\u2019s compounds.<\/p>\n

\u201cChemDiv\u2019s efficiency in producing high-quality, diverse, and medicinal chemistry-friendly compound collections, coupled with their ability to resupply compounds and build upon those initial hits with their Discovery Chemistry services makes ChemDiv a partner of choice for any organization, large or small, who is looking for a partner in small-molecule drug discovery.\u201d<\/p>\n

\u201cWe are thrilled to have the opportunity to partner with Arcus Biosciences,\u201d commented Ron Demuth, General Manager of ChemDiv, Inc. \u201cOne of the most promising companies in the very competitive immune-oncology space and one of the few companies engaged in building a broad portfolio of internally designed small-molecule drugs for use in reversing the immunosuppressive tumor microenvironment; our priority is to help our partner by providing access to all the unique features of our expanding compound collection.\u201d<\/p>\n

About ChemDiv:<\/strong>
\nChemDiv is a recognized global leader in discovery chemistry with one of the industry\u2019s largest, most diverse, and most productive collections of over 1,600,000 individually crafted, lead-like, drug-like small molecules. Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv\u2019s integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. More information: http:\/\/www.chemdiv.com\/<\/a>.<\/p>\n

About Arcus Biosciences:<\/strong>
\nArcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco Bay area, in the heart of the world\u2019s largest biotechnology research hub. More information: https:\/\/www.arcusbio.com\/<\/a><\/p>\n

Media Contact:<\/strong>
\nRonald Demuth
\nSenior VP, Corporate Development & General Manager
\nChemDiv Inc.
\n+1(858)-794-4860×321
\nrdemuth@chemdiv.com<\/p>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.<\/p>\n","protected":false},"author":7053,"featured_media":25635,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[571,602,1,10,61,78],"tags":[],"class_list":["post-25651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-news","category-biotechnology-news","category-business-news","category-california-news","category-health-medical-news","category-san-diego-news","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":5781,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/25651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/7053"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=25651"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/25651\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/25635"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=25651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=25651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=25651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}